-+ 0.00%
-+ 0.00%
-+ 0.00%

OncoZenge board calls SEK 33.3 million rights issue

PUBT·08/27/2026 06:07:23
Listen to the news
OncoZenge board calls SEK 33.3 million rights issue
  • OncoZenge’s board resolved on Aug. 25 to launch a rights issue of about SEK 33.3 million with preferential rights for shareholders.
  • Financing aims to extend cash runway beyond the Phase III BEAM-Pain readout for BupiZenge.
  • Proceeds also earmarked to fund preparation of the Marketing Authorization Application dossier to accelerate approval and launch timelines.
  • Decision followed delays in receiving milestone and investment proceeds, including SEK 10 million still pending from Yangtian Pharma.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncozenge AB published the original content used to generate this news brief on August 27, 2026, and is solely responsible for the information contained therein.